Principaux résultats attendus:
-Two new productsapproved, including medicines that serve the needs of children and other vulnerable patients. Where appropriate, MMV will work with Swissmedic to accelerate endemic country-level approval and WHO prequalification.
- Submission to WHO prequalification ofpaediatric primaquine– the first high-quality child-friendly presentation of this medicine since it was first approved over 60 years ago.
-Expanded roll-outof most recently developed MMV-supported ACT (Pyramax), particularly with a focus on its use to bolster national resistance response strategies.
-Continued supportfor three African manufacturers of critically needed chemopreventive treatments, and addition of a fourth company assisted by MMV.
-Three new moleculesentering human volunteer studies.
-Four to five preclinical candidatesdesigned for the global elimination agenda.
Principaux résultats antérieurs:
- 430 million treatments of a child-friendly medicine calledCoartem Dispersiblefor acute, uncomplicated malaria have been delivered.
- 205 million vials of injectable artesunate (pharmaceutical substance) for the treatment of severe malaria have been delivered.
- 536 million monthly treatment courses of sulfadoxine pyrimethamine and amodiaquine have been delivered to prevent illness and death during malaria season.
- 13 malaria medicines developed and launched
-2.7 million lives have been saved thanks to MMV-supported products.
|